Skip to content
AnalystLens

Neurocrine Biosciences Annual Report, Year Ended Dec 31, 2025

Filing Date
Filed February 11, 2026
Period End
December 31, 2025
Security
NBIX
One revenue dollarkept$0.17
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · Apr ’21Apr ’21
  3. Leadership change8-K · Apr ’25Apr ’25

Summary

Summary of the 10-K filed February 11, 2026. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported total revenues of $2.86 billiona for 2025, up from $2.36 billion in 2024, driven by net product sales of $2.83 billion.

INGREZZA net product sales were $2.51 billionb for 2025 versus $2.31 billion in 2024, and CRENESSITY, launched in December 2024, generated $301.2 million in its first full year. The company's net income rose to $478.6 million, or $4.67 per diluted share, from $341.3 million, or $3.29 per diluted share, in 2024. Operating income was $619.1 million, compared with $570.5 million a year earlier, while research and development spending increased to $1.02 billion from $731.1 million, reflecting Phase 3 programs for osavampator in major depressive disorder and direclidine in schizophrenia.

The company ended 2025 with $2.54 billionc in cash, cash equivalents and marketable securities, up from $1.82 billion, and generated $782.7 million in operating cash flow. It repurchased $167.7 million of stock during 2025 and had $332.3 million remaining under its 2025 repurchase program. Its sales force expansion for INGREZZA and CRENESSITY is expected to be completed by the end of the first quarter of 2026.

Key risks disclosed include a civil investigative demand from the U.S. Department of Justice in August 2025 concerning INGREZZA sales and marketing, a Paragraph IV patent challenge from Zydus relating to INGREZZA SPRINKLE, customer concentration in which four customers represent over 90%d of gross product sales, and Medicare drug pricing pressures under the Inflation Reduction Act. The company also disclosed that two Phase 3 valbenazine studies and a Phase 2 MDD study did not meet their primary endpoints in 2025.

Key Highlights

  1. Total revenues rose to $2,860.5 million in 2025 from $2,355.3 million in 2024, with CRENESSITY contributing $301.2 million in its first full year of sales.
  2. INGREZZA net product sales reached $2,513.7 million in 2025, up from $2,313.5 million in 2024, driven by record total prescriptions partially offset by a lower net price.
  3. Net income increased to $478.6 million ($4.67 diluted EPS) from $341.3 million ($3.29 diluted EPS) in 2024.
  4. Research and development expense increased to $1,015.7 million from $731.1 million, reflecting Phase 3 programs for osavampator in MDD and direclidine in schizophrenia, with initial topline data expected in 2027 for both.
  5. Cash, cash equivalents and marketable securities totaled $2,543.4 million at year-end 2025, up from $1,815.6 million, and operating cash flow was $782.7 million.
  6. The company disclosed an August 2025 civil investigative demand from the U.S. Department of Justice regarding INGREZZA sales and marketing, which it is cooperating with, and an FDA Office of Prescription Drug Promotion untitled letter concerning INGREZZA promotional claims.
  7. Four customers represent over 90% of total gross product sales across INGREZZA and CRENESSITY, and INGREZZA qualifies for the Medicare small biotech exception until 2027.

Follow one dollar

Of each $1.00 of revenue in FY2025, Neurocrine Biosciences kept $0.17.

  1. Revenue$2.86B100.0%
  2. Cost of revenue−$52.1M1.8%
  3. Gross profit$2.81B98.2%
  4. Operating costs−$2.19B76.5%
  5. Operating income$619.1M21.6%
  6. Interest, other & tax−$140.5M4.9%
  7. Net income$478.6M16.7%
Computed from 10-KFY2025filed February 11, 2026Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2025 revenue went

$2.86B
  • SG&A: $1.16B, 40% of revenue
  • Other operating costs: $1.03B, 36% of revenue
  • Net income: $478.6M, 17% of revenue
  • Cost of revenue: $52.1M, 1.8% of revenue
  • Interest, other & tax: $140.5M, 4.9% of revenue

Kept 17% as net income

Full revenue history →

Financial Statements

FY2025 against FY2024

Line itemFY2025FY2024Change
Revenue$2.86B$2.36B+21.4%
Cost of Revenue$52.10M$34.00M+53.2%
Gross Profit$2.81B$2.32B+21.0%
SG&A Expenses$1.16B$1.01B+14.8%
Operating Expenses$2.24B$1.78B+25.6%
Operating Income$619.10M$570.50M+8.5%
Net Income$478.60M$341.30M+40.2%
EPS (Basic)$4.81$3.40+41.5%
EPS (Diluted)$4.67$3.29+41.9%
Shares Outstanding (Basic)99.50M100.40M−0.9%
Shares Outstanding (Diluted)102.50M103.70M−1.2%

Frequently Asked Questions

  1. How much did Neurocrine's product sales grow in 2025?

    Total net product sales increased $503.3 million, or 21.6%, to $2.83 billion in 2025, reflecting growth in both CRENESSITY and INGREZZA, partially offset by a lower net price for INGREZZA due to new market access investments.

  2. What is driving the increase in research and development spending?

    R&D expense rose to $1,015.7 million from $731.1 million, primarily reflecting increased investments in the Phase 3 programs for osavampator in MDD and direclidine in schizophrenia, along with expanded discovery and preclinical programs in endocrinology, obesity, immunology, biologics and gene therapy.

  3. What regulatory or legal matters could affect the company?

    In August 2025 the company received a civil investigative demand from the U.S. Department of Justice related to INGREZZA sales and marketing, and it is cooperating with the request, though the timing and outcome cannot be predicted. The company is also litigating against Zydus over an ANDA filing for a generic version of INGREZZA SPRINKLE.

  4. What share repurchase activity has the company undertaken?

    In February 2025 the Board authorized a $500.0 million repurchase program. During 2025 the company repurchased 1.5 million shares for $167.7 million, leaving $332.3 million available as of December 31, 2025. This followed a $300.0 million accelerated share repurchase program completed in February 2025.

  5. What pipeline milestones are expected next?

    The company expects initial topline data from its Phase 3 programs for osavampator in MDD and direclidine in schizophrenia in 2027, plans to file an IND and begin Phase 1 development of NBIP-2118 for obesity in the first half of 2026, and aims to launch approximately one new medicine every two years.